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Human diseaseMicroRNAs (miRNAs) are small non-coding RNA molecules involved in the expressional regulation of genes
by inhibiting gene translation. MicroRNAs are recruited and incorporated into the miRISC, ribonucleoprotein
complex, targeting speciﬁc mRNAs through mechanisms speciﬁc for a miRNA sequence. Here we review the
biogenesis, regulation, and monitoring of miRNAs, as well as the current evidence for potential roles of
miRNAs in human diseases associated with activation of the endothelin system. These diseases include can-
cer, kidney disease, cardiovascular diseases, inﬂammatory diseases, infectious diseases, and blood diseases,
that may all be aggravated by aberrant miRNA expression. In this review we will also discuss regulatory
mechanisms determining production of miRNA as well as measuring or targeting miRNAs as potential
novel approaches for diagnosis and treatment. Targeting miRNAs possibly will allow one to detect diseases
or to interfere with the progression of diseases associated with activation of the endothelin system.
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The ﬁeld of molecular biology has undergone dramatic changes over
the last decade, due to the advent of new technologies (e.g., different
PCR techniques,microarrays, among others) and due to the accomplish-
ments of the human genome project. These technologies have enabled
us to identify new genes, analyze their functional importance, and link
them to human diseases. These successes have raised our expectations
to the point where we also aspire to ﬁnally unravel the complexity of
disease at the level of molecular interactions in and between cells. An
important discovery was the analysis of microRNAs (miRNAs). Since
their ﬁrst discovery in 1993 (Lee et al., 1993), they have come to be con-
sidered, by some, as the long awaited regulators of gene function and
expression. Not surprisingly, their detection and analysis, among them
is endothelin-1 (ET-1), have been adopted by nearly every research
area. In its ﬁrst section, this review summarizes important aspects of
biogenesis/regulation of miRNAs and the current ways of monitoring
these molecular tools. In the second part, the association between
ET-1 andmiRNAs is highlighted,with particular emphasis on the impor-
tance of differentmiRNAs for the ET-1 signaling axis. Promises aswell as
challenges for the future are discussed.Biogenesis and regulation of miRNAs
Discovery of miRNAs
An excellent system to study developmental and biological processes
is the nematode Caenorhabditis elegans (C. elegans), which was ﬁrst used
in 1974 by Sydney Brenner. The ﬁrst important steps regarding the dis-
covery of miRNAs were performed in C. elegans (Chalﬁe et al., 1981;
Horvitz and Sulston, 1980). These works reported a mutation of the
so-called lin-4 gene (e912), which results in lin-4's loss of function.
This in turn leads to a developmental retardation of the C. elegans
with typical appearances as thin, long adult nematodes with larval
skin (Chalﬁe et al., 1981). This “worm” presents a phenotype in which
early developmental features happen at later time points (Chalﬁe et
al., 1981). The Horvitz group also found that null mutations, and
therefore the loss of function of the lin-14 gene, results in defects in de-
velopmental timing, such as some cells expressing fates earlier in the
development than normal (Ambros andHorvitz, 1984). Ruvkunworked
on cloning lin-14 in the Horvitz lab (Ruvkun et al., 1989). They found
that loss/ null mutations of the lin-14 gene results in exactly the oppo-
site phenotype than loss of the lin-4 gene (Ambros and Horvitz, 1984).
Ultimately, the group detected that a correlation exists between lin-14
and lin-4. The group of Ambros (Lee et al., 1993) found in their later ex-
periments the ﬁrst currently called “pri-miRNA (primary miRNA)”, a
700 bp fragment that contains the lin-4 sequence and either a start or
a stop codon. They concluded that lin-4 did not encode a protein (Lee
et al., 1993). Furthermore, Han et al. (2004) identiﬁed the ﬁrst currently
called “pre-miRNA (precursor miRNA),” which is a 61 nucleotide long
transcript. They also identiﬁed the ﬁrst “miRNA,” which has a size of
22 nucleotides. In parallel, Ruvkun et al. (1989) found that lin-14
was down-regulated at the transcriptional level. They also detected
that the 3′-UTR of the lin-14 gene was necessary for regulation and
that the 3′-UTR sequence has some conserved regions complementa-
ry to lin-4 (Ruvkun et al., 1989; Ambros et al., 2003a). Due to their
complementary data, Ruvkun and Ambros (Ruvkun et al., 1989) shared
their results and the two groups independently came to the sameconclusion, that the small lin-4 gene regulates the lin-14 expression
by binding through the conserved regions at the 3′-UTR (Wightman
et al., 1993). This was the ﬁrst time a small RNA (currently called
“miRNA”) coming from the intron region of gene transcripts and its bi-
ological function was described in the literature (Lee et al., 1993;
Ambros et al., 2003a; Agami, 2010; Zamore et al., 2000). Since that
time, there has been a dramatic increase in the number of newly iden-
tiﬁed miRNAs (currently numbering 1500) and respective targets
(Agami, 2010).
miRNA regulation
In 2001 an important factor in the regulation of miRNAs, Dicer,
was analyzed by two independent groups (Zamore et al., 2000;
Grishok et al., 2001). In the same year, Lau et al. (2001) described an-
other necessary factor in the regulation of miRNAs, called Drosha.
Dicer and Drosha belong to a class of RNA III endonucleases and process
pri- and pre-miRNA to mature miRNA (Kuehbacher et al., 2007). As al-
ready mentioned, there are three different types of miRNA: the
pri-miRNA, pre-miRNA and miRNA. miRNAs can be transcribed from
a single polycistronic transcription unit, so that only one polycistron-
ic sequence produces more than just one functional miRNA and func-
tions as a “miRNA family”, with the same seed sequence but with
different ﬂankings (Lau et al., 2001; Carthew and Sontheimer, 2009;
Kim et al., 2009; Lagos-Quintana et al., 2001; Nelson et al., 2004). In con-
trast, a miRNA cluster deﬁned a region in which more than just one
miRNA can bind, allmiRNAswhich bind in this speciﬁc regionwere called
clustered miRNAs (Yu et al., 2006).
Canonical miRNA biogenesis
The transcription of the miRNA is mediated by RNA polymerase II
(Lee et al., 2004) as well as RNA polymerase III (Borchert et al., 2006).
pri-miRNAs contain a structure that is typical for RNA polymerase II
transcripts. They are 5′-capped, spliced and poly-adenylated at the
3-end (Han et al., 2004). Since 2006 it is known that also RNA poly-
merase III promoters can transcribe miRNAs via the interaction with
Alu sequences, mammalian wide interspersed repeat (MWIR) or
near upstream tRNA sequences (Borchert et al., 2006). Two classical
steps are of great importance in order to produce the mature
miRNA; one taking place in the nucleus and the other one in the cyto-
plasm. The primary miRNA (pri-miRNA) is present in a stem-loop
hairpin structure in the nucleus and is several base pairs long (Fig. 1;
Han et al., 2004). Due to the binding of a micro-processing complex
consisting of a nuclear RNase III type protein, Drosha, and a further pro-
tein, Pasha (DGCR8), the double stranded pri-miRNA is cleaved at the
stem of the hairpin structure into the precursor miRNA (pre-miRNA)
(Han et al., 2004). The DGCR8 was initially described in the literature
in regard to a disease called “DiGeorge syndrome” in which children
have several developmental deformities (Dodson et al., 1969;
Kirkpatrick and DiGeorge, 1968).
The aforementionedmicroprocessor complex has a size of ~650 kDa
in humans. The pre-mRNA binding protein DGCR8 is important for the
orientation and cleavage of the pri-miRNA, due to the position ofDrosha
(Han et al., 2004). The cleavage occurs approximately 11 nucleotides
from the basal segment (Denli et al., 2004). Drosha is important for
the 2 nucleotide overhang on the 3′ end and for adding phosphates on
the 5′ end (Han et al., 2004). The newly formed, double stranded
Fig. 1. General miRNA regulation loop. After the formation of the primary-miRNA (pri-miRNA), two proteins, called DGCR8 and Drosha, are involved in the processing of precursor
miRNA (pre-miRNA). The pre-miRNA is transported from the nucleus to the cytoplasm by the binding of Exportin-5. In the cytoplasm, several different factors (Dicer, TRBP, Ago2
and PACT) form a RISC complex (RNA-induced silencing complex) where the fate of the miRNA is determined by miRNA degradation, storage, or cleavage of the mRNA.
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(Fig. 2a; Lee et al., 2002; Ambros et al., 2003b).Further primary miRNA regulation mechanisms
To date, several different pri-miRNA processing steps have been dis-
covered. The ﬁrst processing step, which is also considered the classical
or canonical step, is the cleavage by the microprocessor complex al-
ready described above.
A further pri-miRNA processing step is DEAD-box RNA helicase de-
pendent (Han et al., 2004). However, except for the pri-miRNA process-
ing step, Drosha and DGCR8 are involved. DEAD proteins are proteins
with a speciﬁc amino acid codon corresponding to the letters (Asp‐
Glu‐Ala‐Asp) (Linder et al., 1989). DEAD familymembers present a spe-
ciﬁc binding site that can be identiﬁed in over 500 proteins and is im-
portant for several different RNA processing steps (Denli et al., 2004;
Banerjee and Slack, 2002). The RNA helicase subunits, p68 and p72,
were identiﬁed as DEAD box family members in 1988 and 1996 (Ford
et al., 1988; Lamm et al., 1996). Lamm et al. (1996) showed that both
proteins localize at the same region in the nucleus of HeLa cells, and
therefore concluded that these proteins are involved in the regulation
of nuclear processes. In 2007, Fukuda et al. published that p68 and
p72 are important for the recognition of primary miRNAs. They
designed mice with knockouts of either p68 or p72, resulting in an
early developmental dysregulation of these mice (Fukuda et al., 2007).
They concluded that some speciﬁc miRNAs need the formation of a
complex consisting of Drosha/DGCR8 and the RNA helicase subunits
p68 and p72 (Fig. 2b; Fukuda et al., 2007).The third important pri-miRNA regulation step is the complex
formation between Drosha/DGCR8-p68/p72 and p53 (Fig. 2c; Fuller‐
Pace and Ali, 2008; Silverman et al., 2003; Suzuki et al., 2009). p53 is a
tumor suppressor gene and is frequently found dysregulated in tumors
(Levine et al., 2004). The tumor suppressor p53 and the DEAD box pro-
tein p68 and p72 build a complex; however, the p53/p72 complex for-
mation is weaker (Fuller-Pace and Ali, 2008). Due to the binding of p53
to DEAD box proteins, different pri-miRNAs processing steps are regu-
lated, especially after DNA damage — where p53 is often found
upregulated (Oba et al., 2010).
The fourth pri-miRNA processing step described in the literature
also includes the Drosha/DGCR8 complex. In this processing step the
complex is combined with ligand-speciﬁc signal transducers (SMAD).
SMAD are downstream subunits in the activation cascade of trans-
forming growth factor, TGF-β and BMPs, and are involved in the
pri-miRNA processing by interacting with a complex consisting of
Drosha/DGCR8 and p68 (Davis and Hata, 2011). Davis et al. published
in 2008 that the R-SMAD alone can regulate the pri-miRNA processing
and that several different miRNA were produced in this SMAD
dependent manner (Fig. 2d; Lamm et al., 1996; Davis et al., 2008;
Davis and Hata, 2011). They claim that a speciﬁc sequence, called the
RNA-SMAD binding element (R-SBE), which is similar to the promoter
region of TGF-β target genes, is important for the correct positioning of
the microprocessor complex (Drosha/DGCR8/p68) (Davis and Hata,
2011).
The ﬁfth pri-miRNA processing pathway depends onmRNA splicing
(Fig. 2e; Berezikov et al., 2007). This mechanism was ﬁrst described in
2007 by Ruby et al. in Drosophila melanogaster and C. elegans (Ruby et
al., 2007). This group observed that some introns mimic the structural
Fig. 2. Schematic illustration of positive pri-miRNA regulation. Beyond the classical miRNA biogenesis pathway (a), several different factors (p68, p72, p53 and R-SBE) have been
discovered joining the omnipresent Drosha/DGCR8 proteins in the generation of the precursor miRNA (pre-miRNA). However, an alternative pre-miRNA producing mechanism has
been demonstrated where introns are directly processed into pre-miRNA. These introns are called “mitrons” (e).
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independent. They called them “mitrons” and identiﬁed 18 mitrons in
the above mentioned organism (Ruby et al., 2007). After splicing,
these mitrons behave like pre-mRNAs where the Exportin-5 binds
through and mediates the transport from the nucleus to the cyto-
plasm where the pre-miRNA matures to miRNA (Gwizdek et al.,
2003; Kim, 2004; Okamura et al., 2007; Yi et al., 2003; Zeng and
Cullen, 2004). Berezikov et al. published in 2007 that the same mecha-
nism exists in mammals. The group also identiﬁed some miRNAs
resulting from splicing, i.e., miR-1129, 1230, and 1231 (Berezikov
et al., 2007). Besides the 5 positive pri-miRNA/miRNA processing
ways described above, four pri-miRNA/miRNA negative regulation
pathways have been analyzed to date (Davis et al., 2008; Sakamoto et
al., 2009; Van Wynsberghe et al., 2011; von Brandenstein et al., 2011;
Yamagata et al., 2009).
The ﬁrst pri-miRNA processing step involves estradiol (E2) stimula-
tion and is estrogen receptor α (ERα) dependent (Suzuki et al., 2009).
In the case of ERα activation via E2 binding, the complex binds to the
Drosha protein and therefore inhibits the binding of Drosha to the
pri-miRNAs. Thus, resulting in the reduction of a subset of miRNAs(Fig. 3a; Davis‐Dusenbery and Hata, 2010; Yamagata et al., 2009;
Castellano et al., 2009).
The second negative regulation loop (Fig. 3b; Sakamoto et al., 2009;
Suzuki and Miyazono, 2010) was analyzed in 2009 by Sakamoto et al.
(2009). The nuclear factors (NF90 and NF45) form a heterodimer in
the nucleus and bind to Drosha and the primary miRNA structure.
This interaction interrupts the processing step from pri-miRNA to
pre-miRNA. The authors claimed that the complex formation increases
the pri-miRNA levels; however, the pre-miRNAs levels decrease
(Sakamoto et al., 2009; VanWynsberghe et al., 2011). This negative reg-
ulation step is important for let-7a family members (Davis-Dusenbery
and Hata, 2010; Davis and Hata, 2009).
The third pri-miRNA negative processing step described in the liter-
ature involves the Lin-28 family. It is often up-regulated in primary
human tumors, while let-7 miRNA is down-regulated (Fig. 3c;
Iliopoulos et al., 2009; Roush and Slack, 2008). A correlation between
Lin-28 and let-7 was ﬁrst described in 2000 in C. elegans (Reinhart et
al., 2000). Van Wynsberghe et al. published in 2011 that Lin-28 can in-
teract with the primary let-7 product and therefore inhibits thematura-
tion to let-7 (Van Wynsberghe et al., 2011; Newman et al., 2008).
Fig. 3. Schematic illustration of negative pri-miRNA regulation. Different proteins are known [ERα and E2 (a); NF90 and NF45 (b); Lin28 (d); PKC α (c)] to inhibit the formation of
pre-miRNA and are therefore responsible for decreasing miRNA levels.
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step involving protein kinase C alpha (PKC α) (Fig. 3d; von Brandenstein
et al., 2011). PKC α builds a complex with NF-κB and MAPK p38 in the
cytoplasm and then theymigrate together into the nucleus. In the nucleus
PKCα binds to the primarymiRNA and inhibits thematuration tomiRNA.
Our group also showed that after the treatment with endothelin-1, the
nuclear PKC α levels decrease, and therefore the miRNA levels increase
(von Brandenstein et al., 2011). Nevertheless, it is uncertain whether
Drosha and DGCR8 were somehow involved in the PKC α regulation.
Our hypothesis is that the binding of PKC α to the loop of the
pri-miRNA 15a has a similar effect as the binding of Lin28 to pri-let7a-1,
namely the inhibition of Drosha binding.
After the cleavage of pri-miRNA to pre-miRNA, with one of the pre-
viously mentioned mechanisms, the pre-miRNA leaves the nucleus.
The nuclear-cytoplasmic shuttling
The ~70 nucleotides long pre-miRNA is produced in the nucleus
and binds to a transport protein, called Exportin-5. This pre-miRNA
then migrates from the nucleus to the cytoplasm (Zeng and Cullen,
2004; Lund et al., 2004). Exportin-5 builds a GTP-Ran complex andis also important for the transport of small RNAs from the nucleus to
the cytoplasm (Lee et al., 2003). The previously Drosha-produced 3′
and 5′ overhangs are important for the recognition and binding of
Exportin-5 (Gwizdek et al., 2003; Zeng and Cullen, 2004; Lee et al.,
2003). The nuclear/cytoplasmic transport via Exportin-5 is cell type
dependent, however, the mechanism behind this is still unknown
(Davis-Dusenbery and Hata, 2010).
Canoncial pre-miRNA to miRNA maturation process
Once in the cytoplasm, the pre-miRNA matures to miRNA. The
so-called RNase III Dicer protein is the most important factor during
this maturation process. The so-called RNase III Dicer protein is the
most important factor during this maturation process. (Davis et al.,
2010; Zhang et al., 2002). Dicer is a highly conserved protein and is
present in every mammalian cell (Zhang et al., 2002). This protein is
important for the proliferation of stem cells, at least in mice, and
the differentiation of neurons and other tissues (Bernstein et al.,
2003; Yang et al., 2005). The Dicer protein cleaves the pre-miRNA
near the base of the hairpin formation, producing the approximately
20 to 22 bp long, double-stranded miRNA (Fig. 1; Zhang et al., 2002;
Fig. 4. Endothelin signaling axis and miRNAs. The ET axis can be inﬂuenced on different levels by known miRNAs, such as: miR125a/b (inhibiting ET-1), miRNA 23 (inhibiting
TGF-β), and miRNA 155 (inhibiting SMAD3). On the other hand, the miRNA 200 family negatively inﬂuences the signal progression of TGF-β via the ZEB transcription factors
and is able to inﬂuence tumor properties in concert with miRNA 15b. EMT, via the endothelin axis, plays an important role in the organ ﬁbrosis of different organ systems such
as the liver, the lung and the kidney, as well as for tumor malignancy. It is identiﬁed by the upregulation of β-catenin, N-cadherin and vimentin. For invasive behavior, integrins
and the integrin-linked kinase activated by ET-1 play an additional modifying role. In prostate cancer, ET-1 via ETAR and the miRNA 15a/16 cluster inﬂuences invasive properties
of tumor cells by modifying the behavior of tumor-surrounding stromal cells. Red arrows = induction of pathway; black bars = blockade of pathway.
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miRNA has a characteristic cleavage site at one end (Gregory et al.,
2005; Zeng and Cullen, 2005). This cleavage site is necessary for the fur-
ther processing of pre-miRNA intomiRNA. Sometimes, it is possible that
both arms are cleaved tomaturemiRNAs. Depending on the arm (either
3′ or 5′) the miRNA is derived from, the miRNAs are called either
miRNA-3p or miRNA-5p.
However, in general only one strandmatures tomiRNA,whereas the
other miRNA strand (without characteristic cleavage site), indicated as
miRNA*, is degraded by a RNA induced silencing complex, i.e., “RISC”.
The RISC complex is responsible for the cleavage of the target mRNA
or translation silencing (P-body storage) (Liu et al., 2005). The newly
formed miRNA can bind to the 3′UTR and triggers the mRNA cleavage.
Alternatively, the target gene is stored in the so-called P-bodies
(processing-bodies), which are involved in the repression of translation
(Brennecke et al., 2005). P-bodies are special cytoplasmic structures
which contain untranslatedmRNAs and serve as translational inhibition
sites (Liu et al., 2005; Teixeira et al., 2005).
Dicer formation in detail
The newly formedmiRNA has a terminal structure typical for RNase
III enzymes cleavage. The PAZ domain of Dicer recognizes this site and
binds through it (MacRae et al., 2007; Saito et al., 2005). The PAZ
(Piwi/Argonaute/Zwille) domain is a 110 amino acid long, evolutionari-
ly conserved region (Yan et al., 2003). In 2005 Haase et al. published
that Dicer builds a complex with TRBP, a human immunodeﬁciency
virus (HIV)-1 transactivating response (TAR) RNA-binding protein.
Truncation of TRBP, and therefore binding behavior change, is found
in tumors frequently correlated with decreasing miRNA levels (Melo
et al., 2009). AnotherDicer binding partner that can also forma complex
with TRBP, is a further double-stranded RNA binding protein called
PACT (protein kinase R-activating protein) (Rossi, 2005). The bindingof these two complex partners is necessary for Dicer stability. TRBP
and PACT are closely related (Melo et al., 2009) and share the same
binding partners, namely PKR and Dicer. The PACT and TRBP proteins
are possible homologues to Loquacious (Loqs) (Kok et al., 2007). This
protein was ﬁrst identiﬁed in Drosophila by (Saito et al., 2005) and is
conserved in all mammals. In Drosophila, two Dicer proteins exist and
Loqs is important for the stabilization of the Dicer complex. Neverthe-
less, only the Dicer1 protein is necessary for the production of miRNAs
in Drosophila. The Dicer2 protein, in contrast, is important for the
siRNA production (Saito et al., 2005; Kim et al., 2006). In humans,
only one Dicer protein (Dicer1) exists and is necessary for the produc-
tion of all small RNAs (Haase et al., 2005). A further protein, called
Argonaute (Ago) can bind to the complex mentioned above. After the
addition of this protein, thewhole complex is called RISC (RNA-induced
silencing complex) (Gregory et al., 2005; MacRae et al., 2007; Faehnle
and Joshua-Tor, 2007). So far, only one miRNA (miRNA 451) has been
described as being processed independently from Dicer (Chelouﬁ et
al., 2010). However, there are several different regulation mechanisms
in the cytoplasm that can also disturb the maturation process.
Regulation of Dicer
Dicer itself can be regulated by several different miRNAs. Forman
et al. (2008) showed that the miRNA let-7 binds to the 3′UTR of
Dicer and is therefore responsible for the Dicer dysregulation. In
2010, Martello et al. showed that in the miRNA-family, miRNA 103/
107 is in the position to regulate Dicer activity. Furthermore, miRNA
expression in human breast cancer is due to binding through the 3′
UTR (3′ untranslated region). This repression of Dicer is associated
with poorer prognosis for patients with this type of cancer
(Martello et al., 2010). An estrogen dependent regulation mechanism
was described by Cochrane et al. in 2011. The group showed that ERα
negative breast cancer cells express high levels of miRNAs (miRNA
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to a direct interaction with the 3′UTR (Cochrane et al., 2011). Recently,
Tao et al. (2011) identiﬁed a further miRNA binding site at the 3′UTR of
Dicer protein. This group showed that the miRNA 18a binds to the 3′
UTR in urinary bladder cancer cells. They reported that this association
has a tumor suppressive effect (Tao et al., 2011). A positive regulation of
Dicer was found in correlation with miRNA 141 in patients with liver
metastasis (Stratmann et al., 2011). Nevertheless, Cochrane et al.
(2011) showed that the miRNA 200c also positively regulates Dicer.
This group also claimed that this positive regulation can be the reason
for the appearance of the well differentiated epithelial phenotype of
breast cancer.
The RISC complex and target genes
The RISC complex, asmentioned above, consists of Dicer, the double-
stranded RNA binding proteins TRBP and PACT, and Argonaute 2 (see
Fig. 1; Rossi, 2005; Faehnle and Joshua-Tor, 2007). The Argo family
consists of 8 different genes. However, Argonaute 2 is the only pro-
tein which is known to cleave the mRNA targets and therefore leads
to mRNA degradation (Faehnle and Joshua-Tor, 2007). An important
role of this complex formation is, as previously mentioned, the un-
winding of the miRNA: miRNA* double strands, and the resulting deg-
radation of the miRNA* strand by the RISC complex (Faehnle and
Joshua-Tor, 2007; Miyoshi et al., 2009). During processing, the miRNA
strand with less thermodynamic stability guides the RISC complex to
the 3′UTR of target mRNAs (Krol et al., 2004). The recognition of the
target gene depends on a so-called seed sequence of the miRNA
(Brennecke et al., 2005). The seed sequence of each miRNA has a size
of 6 to 8 nucleotides and usually starts from the ﬁrst or the second
nucleotide (Brennecke et al., 2005; Doench and Sharp, 2004; Lewis et
al., 2003). The seed sequence is the docking site of miRNA on the 3′
UTR of the target mRNA. Several different databases exist which take
into account themiRNA-mRNA homology and identify possible binding
sites (Lewis et al., 2003; Grifﬁths-Jones, 2006; Maragkakis et al., 2009a;
Kong et al., 2008).
Monitoring miRNAs
Computational approaches to miRNA target identiﬁcation
There are several, freely available programs, which assist in the pre-
diction of a potential binding site for a speciﬁc miRNA. The ones listed
below are primarily for human and mammalian sequences. Since the
programs incorporated in their algorithms differently deﬁned criteria,
a search may retrieve different results than the obtained gene target
list. Thus, it is recommended to combine the results from one's
search in different programs to look for a potentially beneﬁcial overlap
(Bernardo et al., 2011).
DIANA-microT is a software program for detection of miRNA binding
sites, coordinated by Artemis Hatzigeorgiou: (agh@pcbi.upenn.edu)
and Benoit Corda: (cordabe@pcbi.upenn.edu). It is based on several pa-
rameters calculated individually for eachmicroRNA and combines con-
served and non-conserved microRNA recognition elements into a ﬁnal
prediction score, which correlates with protein production fold change.
Speciﬁcally, for each predicted interaction the program reports a signal
to noise ratio and a precision scorewhich can be used as an indication of
the false positive rate of the prediction (Maragkakis et al., 2009b). In ad-
dition, the DIANA-microTweb server is available as the user interface to
the DIANA-microT 3.0 miRNA target prediction algorithm, which offers
links to nomenclature, sequence and protein databases. Thus, users are
facilitated by being able to search for targeted genes using different no-
menclatures or functional features, such as the genes' possible involve-
ment in biological pathways (Maragkakis et al., 2009a).
MicroInspector is a software for detection of miRNA binding sites. It
is run by the Tabler lab at the Institute of Molecular Biology andBiotechnology (IMBB), Heraklion, Greece and University of Plovdiv,
Bulgaria, Dept. of Plant Physiology and Molecular Biology (www.
plantgene.eu). The description of the program is published in the
2005 web issue of Nucleic Acid Research (http://bioinfo.uni-plovdiv.bg/
microinspector). As described by Rusinov et al., the program will ana-
lyze a user-deﬁned RNA sequence, which is typically an mRNA or a
part of anmRNA, for the occurrence of binding sites for known and reg-
istered miRNAs (Rusinov et al., 2005). It allows variation of tempera-
ture, the setting of energy values as well as the selection of different
miRNA databases to identify miRNA-binding sites of different strength.
MicroInspector could spot the correct sites for miRNA-interaction in
known target mRNAs. Using other mRNAs, for which such an interac-
tion has not yet been described, potentialmiRNAbinding sites of similar
quality are reported to be detected frequently, which can subsequently
be analyzed experimentally.
miRanda is an algorithm for ﬁnding genomic targets for miRNAs.
This algorithm has been written in C and is available as an open-
sourcemethod under theGPL.miRandawas developed at the Computa-
tional Biology Center of Memorial Sloan-Kettering Cancer Center. This
software will be further developed under the open source model, coor-
dinated by Anton Enright and Chris Sander (miranda@cbio.mskcc.org).
miRNA.org (http://www.miRNA.org) is a comprehensive resource of
miRNA target predictions and expression proﬁles (Betel et al., 2008).
Target predictions are based on a development of the miRanda algo-
rithm, which incorporates current biological knowledge of target rules
and the use of an up-to-date compendium of mammalian miRNAs.
miRanda reads RNA sequences (such as microRNAs) from ﬁle1 and ge-
nomic DNA/RNA sequences from ﬁle2. One or more miRNA sequences
from ﬁle1 are scanned against all sequences in ﬁle2 and potential target
sites are reported. Potential target sites are identiﬁed using a two-step
strategy. First a dynamic programming local alignment is carried out
between the query miRNA sequence and the reference sequence. This
alignment procedure scores based on sequence complementarity and
not on sequence identity. The second phase of the algorithm takes
high-scoring alignments (Those above a score threshold, deﬁned
by -sc) detected from phase 1 and estimates the thermodynamic stabil-
ity of RNA duplexes based on these alignments.
PicTar is an algorithm for the identiﬁcation of miRNA targets. Pic-
Tar is a project of the Rajewsky lab at NYU's Center for Comparative
Functional Genomics and the MDC, Berlin.
1. miRNA target predictions in vertebrates (Krek et al., 2005)
2. miRNA target predictions in seven Drosophila species (Grun et al.,
2005)
3. miRNA targets in three nematode species (Lall et al., 2006)
4. Human miRNA targets that are not conserved, but co-expressed
(i.e., the miRNA and mRNA are expressed in the same tissue)
(Chen and Rajewsky, 2006)
RNAhybrid is a tool for ﬁnding the minimum free energy hybridi-
zation of a long and a short RNA. The hybridization is performed a
domain-like fashion i.e., the short sequence is hybridized to the best
ﬁtting part of the long one. The tool is primarily meant as a mean
for miRNA target prediction.
TargetScan, from the Whitehead Institute for Biomedical Research
(wibr-bioinformatics@wi.mit.edu), predicts biological targets of
miRNAs by searching for the presence of conserved 8mer and 7mer
sites that match the seed region of each miRNA (Lewis et al., 2005).
As an option, non-conserved sites are also predicted. Also identiﬁed
are sites with mismatches in the seed region that are compensated
by conserved 3′ pairing (Friedman et al., 2009).
In addition there are programs speciﬁcally tailored to miRNA: 3′
UTR intermolecular interactions such as “Sylamer” (Alexiou et al.,
2009; Selbach et al., 2008).
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As alreadymentioned, several different databases existwhich can be
used to detect possible miRNA–mRNA interaction sites. However, it is
necessary to show this interaction via appropriate experiments. It is
not enough to show a correlation between the increases or decreases
of target gene levels and miRNA levels in culture or tissues, because
this correlation can be “true or true and unrelated”. The databases are
usable for the identiﬁcation of possible binding sites, but a regulation
of a possible target sequence should be supported with experiments,
e.g., use of mimics, si-RNAs and reporter assays.
Isolation and monitoring of miRNA
miRNA can be isolated from tissue (either fresh or parafﬁnized), cell
culture, and body liquids. Until now it was possible to isolate miRNAs
from: serum, plasma, cerebrospinal ﬂuid, sputum, ejaculate, vaginal se-
cret, menstruation blood, breast milk, sweat, and urine (Etheridge et
al., 2011; Gilad et al., 2008; Hanson et al., 2009, Kosaka et al., 2010a,
2010b; Mitchell et al., 2008). In general, monitoring the miRNA gene
expression proﬁles was used for the identiﬁcation of miRNAs. Different
methods can be used for analysis, however, the most common ones in
monitoring miRNA expression proﬁles are, e.g., Northern blot analysis,
quantitative Real-time PCR (qRT-PCR), microarray analysis, and in situ
hybridization (de Planell-Saguer and Rodicio, 2011).
Detection of miRNAs for diagnostic purposes
To date, several methods have been in use to detect miRNAs. These
include: Northern blot analysis with radiolabeled or biotinylated pro-
bes, microarray based technology, single-molecule detection in liquid
phase, in situ hybridization, and high-throughput sequencing. Since all
techniques have their speciﬁc limitations, the one “ideal” for the
planned experiment depends upon the speciﬁc experimental setting.
Microarray and next generation/deep sequencing
With microarray technology, the relative change of expression
(rather than the absolute abundance) is determined mostly within the
context of healthy versus diseased tissue or untreated versus treated
disease. Its setback is the requirement of sequence information for
probe design. Here, next generation sequencing, also called “deep se-
quencing”, being able to sequence shorter fragments of DNA/RNA, is
able to overcome the sequence limitation of microarrays. This technol-
ogy provides information on all RNA species and their absolute abun-
dance, even allowing detection of previously unknown small RNAs/
miRNAs. However, since terabytes of data are generated, extensive
computational data storage and analysis capacities are required to ana-
lyze the result. Furthermore, functional experiments have to be per-
formed to substantiate the data.
Quantitative real-time PCR (qRT-PCR) is probably currently the
most frequently and widely used technique. It can be applied with 2
different technologies: i) stem-loop speciﬁc primers binding to the
3′ end of the miRNA followed by individual reverse transcription
and a TaqMan miRNA assay, or ii) adding a poly(A) tail to the 3′
end of all miRNAs by using a universal primer. The ﬁrst approach,
being more expensive, is able to differentiate between mature and
pri/pre-miRNAs. The second approach, being cheaper, is useful if dif-
ferent miRNAs have to be analyzed in a small starting material, but
does not differentiate between precursor miRNAs.
Northern blotting, being time consuming and requiring a relative
large amount of RNA (at least 10 μg), is not only a robust and well
established method, but it also remains the only one to differentiate
mature from pre-miRNA. With the invention of the so-called locked
nucleic acid (LNA) probes, the sensitivity over common radiolabeled
DNA probes for the detection of RNA molecules of small size andlow abundance is greatly improved (for further details see Varallyay
et al. (2008)). Finally, in situ hybridization is advantageous, if the dis-
covery of spatiotemporal expression of miRNAs is requested, in help-
ing to unravel the biologic role. The method works well for highly
abundant miRNAs, but is inconsistent for miRNAs in low abundance
(for further details see Jorgensen et al., 2010; Obernosterer et al.,
2007; Pena et al., 2009; Silahtaroglu et al., 2007; Song et al., 2010).
Less common methods include electrochemical detection, such as
nanotechnology, bioluminescence miRNA detection as competitive
solid-phase hybridization based method, surface-enhanced Raman spec-
troscopy method, or surface plamon resonance imaging (SPRI)-based
methods (for further details see de Planell-Saguer and Rodicio, 2011).
Regulation and functional analysis
Further experimental analyses are imperative in order to validate
a result as the direct effect of one speciﬁc miRNA. There are several
reasons for this demand: i) the samemiRNA is potentially able to reg-
ulate different genes at the same time, as well as one gene being po-
tentially regulated by different miRNAs; ii) sequence homology
between the gene region and the so-called seed-sequence (+/− its
ﬂanking sequence) does not necessarily mean that an interaction
will actually take place; iii) there may be several miRNAs with
cross-matching sequence homology, of which only one may actually
bind. The latter two phenomena are as yet unexplained. They can be
observed when comparing miRNA binding between species: the pu-
tative binding site for miRNA 17-3p, being well conserved in different
animal species and in humans, only allows interaction with the
expected miRNA in animals, but not in humans (unpublished data).
miRNAs having the same seed sequence may still not bind to their re-
spective binding site at a given gene.
To study functional effects, the primary choice will be the in vitro
cell culture to study the efﬁcacy of miRNAs in question. For further
analysis of more complex pathophysiologic interactions, in vivo ani-
mal models may have to be employed.
Antisense oligonucleotides (ASO) and anti-mRNA oligonucleotides
(AMO) have been used to modulate endogenous miRNA levels. The
work principle is identical: the single-stranded oligonucleotide pairs
with its complementary part of the miRNA and prevents mRNA target
interaction. Different modiﬁcations have been used to prevent nucle-
ase degradation and endonucleolytic damage by the RISC complex
(Lennox and Behlke, 2011). The study by Esau et al. (2004) which an-
alyzed miRNA patterns in adipocyte differentiation is a recent exam-
ple of experimental work using ASOs targeting. The potential for
using AMOs in a variety of human diseases, such as: neurodegenera-
tive illnesses, cancer, viral infections, and metabolic disturbances, has
been outlined by Weiler et al. (2006).
For in vitro experiments, different experimental aspects have to
be considered: i) the speciﬁc characteristics of each cell line used,
ii) optimizing inhibitor concentration depending on potency and efﬁ-
ciency of delivery, iii) the assay time itself, iv) cell type variations in
loss or gain of function when comparing results, and v) the need for
stressing cells to visualize phenotypic changes induced by miRNA
inhibition.
For in vivo inhibition in animalmodels, anti-miRNAs have been pro-
posed, which are partially or fully complementary to the mature
miRNA target. Their effect should be a successful suppression of the
miRNA in question and leading to increased target mRNA and protein
levels. These reagents have to fulﬁll several requirements: i) high
cell-permeability, ii) slow excretion, iii) stability in vivo, iv) high bind-
ing speciﬁcity and an afﬁnity to the target miRNA, and v) low toxicity
and side effects in other organs or off-targets. Particularly the last re-
quirement has to be carefully considered because of the systemic de-
livery of these reagents. Furthermore, the desired knockdown effect
has to be conﬁrmed in the target tissue by qRT-PCR or Northern blot-
ting, the protein upregulation monitored by Western blot, and
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cluded by a histopathologic analysis particularly of the liver and
kidneys.
Two principle antimiRNA modiﬁcations are currently in use:
1) 2′-0-Methyl group-modiﬁed oligonucleotides, also called antagomiRs
2) Locked-nucleic-acid (LNA)-modiﬁed oligonucleotides
The antagomiRs have been observed after tail vein injection in mice
as being able to induce as well as suppress genes in vivo (Krutzfeldt et
al., 2005) in a variety of organs, except the brain, while an immune re-
sponse was not reported. However, relatively high doses (~80 mg/kg)
and occasionally up to three injections are required (Bernardo et al.,
2011).
LNA-oligonucleotides, have an improved resistance to degradation,
and at the same time stabilize the miRNA-target duplex structure that
is crucial for silencing activity. They have been preferably used in in
situ hybridization (Doench et al., 2003). For in vivo experiments in
non-human primates (Elmen et al., 2008) or by injection into the hearts
of mice (Patrick et al., 2010; Porrello et al., 2011) usability has been
reported. The use of lower doses due to their high afﬁnities (Petersen
et al., 2000) and a long lasting effect (60 days) was described.
Viral vectors expressing miRNAs
Viral vectors have been used for gene therapy and pharmaceutical
target validation. While retroviruses need genomic integration and
dividing cells, lentiviral vectors integrate into nondividing cells. In
contrast, adenoviral or adenoassociated viral (AAV) vectors remain
cytoplasmatic. These methods, however, while potentially able to pro-
duce the desired miRNA for a short or a long term, still pose several
problems for their use. Themost important problem is targeting the de-
livery into the desired cells/tissue by injection. At the same time, side ef-
fects, due to expression in other organ systems, pose a potential threat.
Integration will provide prolonged, but not controllable production in
either rapid proliferation cells (tumor), suitable for retrovirus delivery,
while lentiviruses are more suited for organs with low cell division
(heart, brain). Adenoviral or AAV vectors will only allow short term
gene production, due to their non-integration. Secondly, limiting the
expression to a certain cell type would greatly improve the speciﬁcity
of themiRNA effect. Here, expression constructs with target cell speciﬁc
or inducible (Epanchintsev et al., 2006) promoters could prove effective
and prevent side effects.
Diagnostic relevance
Over the last years, since it became known that miRNAs: can reg-
ulate a variety of developmental processes, are involved in cell prolif-
eration, in tumor development and in other diseases, this research
area has exploded (Alvarez-Garcia and Miska, 2005). Due to the fact
that miRNAs can release the cells either via vesicles, or as recently
shown, in complex with Ago2, miRNA is accessible for diagnostic pur-
poses (Arroyo et al., 2011; Hunter et al., 2008). In the recent past,
studies monitoring the miRNA levels have been done in several differ-
ent diseases and tumors. In 2010, Brase et al. (2010) published that two
miRNAs (miRNA 375 and miRNA 141) are detectable in patient blood
samples and that miRNA detection can be used as a diagnostic marker.
Wulfken et al. (2011) published that the free circulatingmiRNA 1233 is
a potential biomarker for the detection of clear cell renal carcinoma
(RCC). Furthermore, Roth et al. published in 2010 that the analysis of
twomiRNAs (miRNA 10b andmiRNA 34) in patients with breast cancer
can possibly be used as a diagnostic marker.
Our group recently showed the regulation mechanism of miRNA
15a, which is protein kinase C alpha (PKC α) dependent (von
Brandenstein et al., 2011). Furthermore, we also showed that the de-
tection of miRNA 15a in urine samples from patients with RCCs, themalignant variant of kidney tumors, compared to oncocytoma, the
benign variant, can possibly be used as a diagnostic marker (von
Brandenstein et al., 2012).
Endothelin signaling and associated miRNAs
While in 2011, hundreds of articles were published reporting the
new roles of miRNAs in many pathophysiologically different human
disease entities, only a few articles can currently be found linking
endothelin with miRNAs. In the following review section, these arti-
cles will be brieﬂy discussed. They will be used as a starting point in
analyzing other disease entities in which the respective miRNA may
play a role although a possible relationship with endothelin itself
has not been investigated in these articles. In many of these disease
entities endothelin is in fact involved in the underlying pathophysio-
logic process, and may therefore indicate the need for new avenues of
research.
miRNA 15
This miRNA has been implicated in different pathophysiologic events,
being either up- or downregulated. Recently, von Brandenstein et al.
(2011) have shown that ET-1 is able to induce a transcription complex
consisting of NF-κB p65, MAPK p38 alpha, and PKC alpha in different
tumor cell lines from renal cell carcinoma, cervical cancer, andmelanoma.
This complex migrates into the nucleus, where PKC alpha is able to pre-
vent pri-miRNA 15a from transmigrating into the cytoplasm by binding
to the pri-miRNA stem loop. Subsequently, cytoplasmic levels of miRNA
15a drop, sincemiRNAmaturation is prevented. If miRNA 15a is stimulat-
ed in abundance (and PKC alpha levels low) as in clear cell renal cell car-
cinoma, it can be released in the urine. Here, the miRNA can be detected
by qRT-PCR. This provides a diagnostic tool for renal cancer derived
from the proximal tubule (von Brandenstein et al., 2012), because
tumor removal by nephrectomy drops miRNA levels to background
values. In contrast, in the benign renal tumor, the so-called oncocytoma,
the situation is reversed: PKC alpha levels are high and miRNA levels
are low.
miRNAs encoded by the miRNA 15/16 cluster are known as tumor
suppressors. They inhibit cell proliferation, promote apoptosis of can-
cer cells, and suppress tumorigenicity both in vitro and in vivo
(Aqeilan et al., 2009). Multiple oncogenes have been described as tar-
gets, including: BCL2, MCL1, CCND1, and WNT3A (Bonci et al., 2008).
These miRNAs are downregulated in chronic lymphocytic lymphoma
(Calin et al., 2008), pituitary adenoma, multiple myeloma (Roccaro et
al., 2009) and prostate carcinoma, and in a subset of non-small cell
lung cancer (Bandi et al., 2009).
In the prostate, both endothelin receptors are present on stromal
and epithelial cells (Kobayashi et al., 1994). The ETB receptor is re-
pressed by methylation, while activation of the ETA receptor provides
an advantage for survival. Here, ET-1 treatment in prostate cancer in-
hibits apoptosis of tumor cells, in part through the Bcl-2 family. Family
members Bad, Bax, and Bak are decreased; however, Bcl-2 itself remains
unchanged (Nelson et al., 2005). In the tumor-supportive stromal cells,
miRNAs 15a and 16 are downregulated in cancer-associated ﬁbroblasts.
Such downregulation promotes tumor growth and progression through
the reduced post-transcriptional regression of Fgf-2 and its receptor
FgfR1, which both act on stromal and tumor cells alike to enhance can-
cer cell survival, proliferation, and migration (Musumeci et al., 2011).
In autosomal-dominant polycystic kidney disease, Hocher et al.
(1998) have demonstrated that the endothelin system plays a role in a
paracrine manner. It participates in the regulation of mean arterial
blood pressure, glomerular ﬁltration rate, and renal blood ﬂow. Further-
more, Ong et al. (2003) have found that ET-1 is expressed in cyst epithelia,
mesangial cells, and vascular smooth muscle cells. ETA receptor was
also expressed in glomeruli, cysts, and medium-sized renal arteries by
microautoradiography. Recently, Lee et al. (2008) have associated
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They found decreased amounts of miRNA 15a in livers of patients
with autosomal recessive and autosomal dominant kidney disease,
as well as in congenital hepatic ﬁbrosis. This resulted in the increased
expression of the cell-cycle regulator Cdc25A. Cdc25 is a direct target
of miRNA 15a, and increased cellular proliferation and cystogenesis in
vivo.miRNA 23
In the literature, endothelin-1 (besides phenylephrine and pressure
overload) has been described as upregulating the endogenous miRNA
23a in cardiac muscle cells. When overexpressed in transgenic mice,
cardiac hypertrophy ensues by direct inhibition of the translational ac-
tivity of Foxo3a 3′UTR by miRNA 23a (Wang et al., 2010). In addition,
miRNA 23a is able to alter expression levels of Manganese Superoxide
Dismutase and the consequent reactive oxygen radicals. This observa-
tion was reported by Lin et al. (2011), who likewise discovered oxygen
radical protection by miRNA 23a in the context of human retinal pig-
ment epithelial cells. This is mediated by interaction of this miRNA
with a binding site at the 3′UTR of the FAS gene. In endothelial cells,
miRNA 23a, together with other members of its cluster (miRNA 27,
miRNA 24), may also play an important role in the regulation of murine
angiogenesis and neovascularization; through targeting SPRY2 and
Sema6A proteins (Zhou et al., 2011). In addition, miRNA 23a has a
role in restricting cardiac valve formation, since it is both necessary
and sufﬁcient for restricting the number of endocardial cells that differ-
entiate into the endocardial cushion (Lagendijk et al., 2011). Thus, it can
be speculated that a miRNA 23a dysregulation may be involved in the
development of the so-called endocardial cushion defects as described
by Rastelli et al. (1966). In addition, Lagendijk et al. (2011) have de-
scribed that miRNA 23a is able to inhibit a transforming growth
factor-β induced endothelial-to-mesenchymal transition in mouse en-
dothelial cells, thus preventing a further contribution to potential ﬁbro-
sis (see Fig. 4). However, miRNA 23a is also known to participate in
the progress of cellular senescence: in (human cord-blood derived)
multi-potent stem cells it participates in the down-regulation of the
high mobility group A2, while helping to upregulate p16(INK4A),
p21(CIP1/WAF1) and p27(KIP) (Lee et al., 2006). In this context, one ﬁnds
miRNA temporally and spatially regulated in (neuroepithelial) stem
cells (Farrell et al., 2010). Thus, in the brain miRNA 23 participates in
the myelination process through regulation of laminin B1 and appears
crucial for oligodendrocyte development (Aqeilan et al., 2009).miRNA 125
In cardiovascular disease, different mediators are able to stimu-
late endothelial cells causing dysregulation, among them are oxi-
dized low-density lipoproteins. One particular reaction is the
upregulation of endothelin-1. Le et al. (2009) have shown that
miRNA 125a-5p and 125b-5p prevent this upregulation by directly
targeting the 3′UTR of pre-pro-endothelin mRNA (Aqeilan et al., 2009).
Thus, this miRNA may be important because it is able to prevent endo-
thelin production. Thiswill prohibit the signaling cascade via ETA receptor
leading to epithelial–mesenchymal transformation which is the basis for
ﬁbrosis. Since thismiRNA is also reported as a regulator of p53, by binding
to its 3′UTR in humans and zebraﬁsh (Aqeilan et al., 2009), it should
play a role in preventing the epithelial–mesenchymal transformation
(EMT) (see Fig. 4). p53 upregulates members of the miRNA 200 family,
which in turn decreases the TGF-β‐mediated‐transcription factor ZEB1,
leading to reduced EMT formation. Another role of miRNA 125 is its par-
ticipation in the downregulation of p53 in oral lichen planus (Aqeilan et
al., 2009), a condition in which endothelin is upregulated (Chang et al.,
2011).miRNA 155
This miRNA is necessary to upregulate endothelin-1 in liver sinu-
soidal endothelial cells in humans but not in the rat (Yeligar et al.,
2009), after ethanol-treatment, potentially modifying the inﬂuence
of ET-1 in this micro-environment. At the same time, ethanol dam-
age resulting in progressive liver ﬁbrosis is potentially attenuated
by the negative modulating effect of this miRNA on SMAD2 expres-
sion (see Fig. 4), since Bala et al. (2010) have found two predicted
target sites in SMAD2 3′UTR. In non-alcoholic steatohepatitis (NASH)
patients, where fat accumulation leads to inﬂammation and subsequent
ﬁbrosis, Degertekin et al. (2007) observed that the serum ET-1 level
showed a statistically signiﬁcant increase as ﬁbrosis severity increased.
This ET-1 increase could well be mediated by the difference in expres-
sion of hepatic miRNAs such as miRNA 155, as was observed in a
mouse model of dietary, non-alcoholic steatohepatitis (Pogribny et al.,
2010). Since inﬂammation is a part of the development of NASH, it is
not surprising that this miRNA is involved in the different aspects of
the inﬂammatory signaling pathways in which ET-1 participates. In
the pathogenesis of alcoholic activation of von Kupffer cells, miRNA
155 as well as NF-κB being upregulated will contribute to an increased
tumor necrosis factor alpha production. Furthermore, Thompson et al.
(2010) showed thatmiRNA155was an actual target for theNF-κB path-
way, and leads to the reduced expression of different transcription
factors in several B-lymphoma cell lines. Since ET-1 induces a transcrip-
tion complex containing NF-κB in different normal and tumor human
cell lines (von Brandenstein et al., 2008), this miRNA should be consid-
ered as playing an important, yet unidentiﬁed, role in these cells. Not
surprisingly, miRNA 155 has been shown as a pro-inﬂammatory regu-
lator in clinical and experimental arthritis, a disease entity in which
ET-1 is regarded as playing a major role and NF-κB is activated
[rheumatoid arthritis, (Kurowska-Stolarska et al., 2011)]; [osteoar-
thritis, (Roy-Beaudry et al., 2003)]. Furthermore, this miRNA has been
shown to participate in autoimmunediseases,where it canpromote auto-
immune inﬂammation by enhancing inﬂammatory T-cell development
(O'Connell et al., 2010). In systemic lupus nephritis (Wang et al., 2010)
miRNA 155 is elevated in the urine, just as ET-1 levels are (Dhaun et al.,
2009). Finally, immortalization of B-cells by Epstein–Barr virus (EBV) is
dependent upon virally induced miRNA 155 (Linnstaedt et al., 2010),
while as a negative regulator of EBV disease, miRNA 155 can prevent
bonemorphogenic protein (BMPs: 2, 6, and 7)‐mediated EBV reactivation
(Yin et al., 2010). Regarding bone morphogenic proteins, miRNA 155
could also play an important part in early autoimmune diabetes, where
it may support the role of the ETA receptor in negatively regulating acti-
vated BMPs 2 and 7 (Nett et al., 2006).
miRNA 195
Sickle cell disease is a model for a chronic inﬂammatory state with
increased circulatory levels of pro-inﬂammatory cytokines. Here, pla-
cental growth factor induces endothelin-1 in the pulmonary microvas-
culature. ET-1 was able to signiﬁcantly downregulate miRNA 195. This
miRNA has a complimentary binding site in the 3′UTR of the chemokine
CCL4. Signaling occurs via the activation of: PIK3A, p38 MAPK, NF-κB,
and hypoxia-inducible factor-1 alpha (Gonsalves and Kalra, 2010).
miRNA 195 is also known for its involvement in cell cycle regulation. Al-
though not yet proven, ET-1 and miRNA 195 may work together in
achieving apoptosis. Recently, von Brandenstein et al. (2012) described
the upregulation the tumor suppressor gene p16INK4a by the activation
of the ETS-binding site of the p16 INK4a promoter through anET-1 induc-
ible, ETS/ERK2/Mxi-2 transcription complex. It is also known that
p16INK4a shows aging dependent changes in its phosphorylation proﬁle
and increasingly associates itself with cdk4- and cdk6. This leads to a
loss of cyclin D1 binding, preventing cell cycle progression (Sandhu et
al., 2000). Since miRNA 195 is able to downregulate several G(1)/S
transition-related molecules (cyclinD1, CDK6, and E2F3) as its direct
485M. von Brandenstein et al. / Life Sciences 91 (2012) 475–489targets (Sandhu et al., 2000), at least a concerted action of ET-1 and
miRNA 195 has to be assumed.
miRNA 199 and the miRNA 200 family
Different research groups have recognized the importance of the
endothelin signaling axis in the progression of different diseases leading
toﬁbrosis. This particular process is based on the epithelial–mesenchymal
transition, so-called EMT (see Fig. 4). It could be identiﬁed in the liver
(Yeligar et al., 2009; Degertekin et al., 2007), lung (Crestani, 2007; Jain
et al., 2007) and kidney (Oba et al., 2010) as well as in tumors, such as
ovarian cancer (Bagnato and Rosano, 2007; Rosano et al., 2011; Vergara
et al., 2009). Epithelial–mesenchymal transition (EMT) is a prime exam-
ple of a reversible differentiation process that occurs during normal
development, such as neural tube and mesoderm formation during em-
bryogenesis [Type I EMT, (Carew et al., 2011)]. Two other types of EMT
have been recently described: type II in organ ﬁbrosis, wound healing,
and regeneration; and type III in cancer metastasis (Carew et al.,
2011). In type III, EMT has been highlighted as a key process in
tumor invasion, metastasis and tumorgenicity (Kong et al., 2008;
Wellner et al., 2009), enhancing the invasive properties of epithelial
tumor cells and promoting tumor metastasis (Berx et al., 2007;
Thiery, 2002). Mani et al. (2008) have shown that this process
is also associated with the acquisition of tumor initiating and
self-renewal properties. The potential for a forward-and-back conver-
sion between the epithelial and the mesenchymal state has also been
recognized as inﬂuencing tumor malignancy (Gupta et al., 2009;
Polyak and Weinberg, 2009).
EMT is promoted by transforming growth factors (TGFs), such as
TGFB1 (TGFβ1) and TGFB2 [TGFβ2; (Thiery and Sleeman, 2006)]. TGF-β
has been found to play an important role in particular stages of develop-
ment and in disease processes, such as ﬁbrosis and cancer metastasis
(Derynck and Akhurst, 2007; Pardali and Moustakas, 2007; Zeisberg
and Kalluri, 2004). Several EMT-activating transcription factors: ZEB1
(also called dEF1, TCF8, and AREB6), ZEB2 (also called SIP1), SNAI1 (also
called Snail), SNAI2 (also called Slug), and TWIST involved in this process
have been previously identiﬁed (Kong et al., 2008). They are TGF-β
induced, and mediate its effects at least in part through repression of
E-cadherin and initiation of EMT (Peinado et al., 2007).
It has been recently reported that miRNAs may play a crucial role in
EMT. The miR-200 family was found to target ZEB1 and ZEB2, while
being themselves signiﬁcantly down-regulated in TGFβ-induced mes-
enchymal cells and cancer cells with mesenchymal characteristics
(Mitchell et al., 2008; Bracken et al., 2008). Several investigations
have shown this family of miRNAs involvement in progressive ﬁbrosis
and epithelial-to-mesenchymal-transformation in a variety of organs.
In the liver, sinusoidal endothelial cells have been demonstrated to
be the source of increased mRNA expression of endothlien-1, hypoxia-
inducible-factor-1 alpha, and inﬂammatory cytokines in ethanol-fed
rats. However, the regulatory mechanism to control transcription was
unknown. In a rat model of liver damage by ethanol-feeding, Yeligar
et al. (2009) demonstrated that miRNA 199 plays a major role as a neg-
ative regulator to control transcription and homeostatic levels of ET-1,
leading to a controlled microcirculatory tone. In non-alcoholic liver
steatohepatitis (NASH), ET-1 levels have been found to be upregulated
in the serum of NASH patients (Degertekin et al., 2007). In a respective
murine model, upregulation of miRNA 200b has been observed, among
others, indicating that the severity and susceptibility of NASH may be
determined by variations in miRNA expression response. Furthermore,
in a CCL(4)-induced mouse model, miRNA 199a and 200a and b were
found positively and signiﬁcantly correlated to the progressed liver ﬁ-
brosis (Murakami et al., 2011). In addition, these miRNAs could be
detected in liver biopsy specimens from 105 chronic hepatitis type C
patients without a history of anti-viral therapy (Murakami et al., 2011).
It is known that ET-1 is an initiator of EMT (Fukuda et al., 2007) in
the lung, where it helps to transform alveolar type II cells (Crestani,2007). This process is mediated through the ETA-receptor, leading to
the upregulation of TGF-β (Jain et al., 2007). The participation of
miRNAs was not investigated in these experimental settings, since
their potential role was still unknown at the time. However, given the
almost identical signal-setting, members of the miRNA 200 family and
other miRNAs can be expected to participate in this process.
In the kidney, the severity of tubulointerstitial ﬁbrosis correlates not
only with the risk of progressive renal dysfunction, but is also the most
important factor for long termprognosis, particularly in diabetic nephrop-
athy (Gilbert and Cooper, 1999). In proteinuric diseases, the activation of
proximal tubules (Laghmani et al., 2002) by protein and other mediators
leaking through the damaged glomerular capillarywall have been shown
to induce ET-1 with tubulointerstitial ﬁbrosis and EMT (Hocher et al.,
1997). Thus, it is not surprising that in a model of unilateral ureteral ob-
struction mimicking EMT formation, the use of a miRNA 200b precursor
led to an ameliorating effect on tubulointerstitial ﬁbrosis with prevention
of increased collagen types I and III as well as ﬁbronectin deposition. This
miRNA could be shown to act via the suppression of TGF-β induced ZEB 1
and 2 transcription factors.
Currently, the only tumor studies investigating the effects of the
endothelin axis on EMT have been performed in ovarian cancer
(Bagnato and Rosano, 2007). The expression of an EMT phenotype
as well as the acquisition of chemoresistance could be linked to the
activation of the endothelin A receptor pathway (Rosano et al.,
2011). Activation of the ETAR by ET-1 enhanced the expression of
α2 β1 and α3 β1 integrins. This is associated with an increase in
the activity of the integrin-linked kinase once ovarian cancer cells ad-
hered to type 1 collagen (Rosano et al., 2006). Speciﬁc blockage of the
ETAR was able to downregulate SNAIL activity and to restore sensitiv-
ity to cytotoxic-induced apoptosis as well as inhibiting the invasive-
ness of resistant tumor cells.
MicroRNAs: promises, challenges, and future directions
The discovery of miRNAs holds promises and challenges for the fu-
ture of clinical practice. First impacts have affected the ﬁelds of thera-
peutic targeting and disease detection. miRNAs may be able to be
therapeutically controlled without the adverse side effects of current
molecular approaches (Fasanaro et al., 2009; Montgomery and van
Rooij, 2010; Seto, 2010). Toward that end, the report of a successful
Phase I trial using LNA anti-miRs for the treatment of hepatitis C (see
Bernardo et al., 2011) is encouraging, particularly since its quality was
so convincing that a Phase II clinical trial was added (Santaris Pharma
A/S, clinical trial identiﬁer NCT01200420) (see Bernardo et al., 2011).
In the ﬁeld of cancer, one could envision analyzing the miRNA pattern
of a patient's tumor sample bymicroarray as the ﬁrst step of amultistep
process in individualizing cancer therapy. Combined with additional
molecular studies in the patient and even in relevant family members,
this analysis could greatly help in tailoring the patient's future therapy.
Furthermore, miRNA analysis may aid in cancer detection. Recently,
Barker et al. (2009) has reported that miRNA pattern recognition
could be able to identify the histogenetic origin of a CUP syndrome
(cancer of unknown primary).
In the ﬁeld of disease detection, miRNAs may play a role as bio-
markers. Again, limitation of the current biomarkers may be avoided,
such as reduced sensitivity, speciﬁcity, detectability only in already ad-
vanced lesions, and costly methods employed. miRNAs appear to be
ideal biomarkers compared to currently available ones because of
their: presence and stability in serum/blood (Gilad et al., 2008), and in
urine (von Brandenstein et al., 2012), relatively easy detectability (by
qRT-PCR), stability even after freeze-thaw cycles, and potential speciﬁc-
ity to tissue or disease states. Several studies have been publishedwhich
use the detection of miRNA in serum/blood as potential diagnostic or
even prognostic indicators, such as in diabetes, cardiovascular disease
or cancer (references — see Bernardo et al. (2011)). We have recently
proposed that miRNA 15a could serve as biomarker for differentiation
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samples (von Brandenstein et al., 2012).
In spite of these encouraging developments, challenges on at least
3 different levels remain before a widespread use of miRNAs can be
employed:
i) Understanding of the processing of miRNA itself
The mechanisms of modiﬁcation, stabilization, degradation,
and turnover are largely unknown. Additional regulatory
pathways may yet to be discovered [such as PKC α regulating
miRNA 15a (von Brandenstein et al., 2011)]. New discoveries
of unconventional pathways even in the regulation of miRNA
biogenesis, such as the one without Drosha and DGCR8
(Fig. 3e) may change our thinking of miRNA processing in
the future.
ii) The promiscuous effect of miRNAs and their interactive generation
cascades.
A single miRNA may be able to regulate different genes as well
as several miRNAs that are involved in the regulation of the
same gene (Suzuki and Miyazono, 2010). Here the speciﬁcity
of gene–miRNA interaction has to be deﬁned, and the potential
functional effects of different miRNA interactions for gene ex-
pression characterized to prevent undesired or damaging side
effects by losing tissue speciﬁcity.
iii) Functional miRNA redundancy and interaction
Quite similar to transcription factors, miRNAs are often clus-
tered in families of highly related members, carrying out po-
tentially distinct biological functions. Binding characteristics
and the miRNA–miRNA interactions have to be deﬁned, as a
fundamental necessity, prior to any efforts of therapeutic
targeting.
The challenges in unraveling the mysteries of the miRNA
micro-cosmos will be numerous, but the potential rewards will
be equally unimaginable. Surely, the roads of exploration will
provide us with a new understanding of biology and the intrica-
cies of nature.Abbreviations
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